In this interview Shahzad Raza, MD, discusses a study on the treatment of patients with extramedullary myeloma, as presented at ASH 2025.
“I found this to be a really exciting study. I don’t think we can do this type of study in the future easily, because these are very complex and very challenging studies. But I do see a light here for our patients who have this type of bad multiple myeloma, which is difficult to treat, and we can actually offer them this type of therapy,” said Raza, a hematologist-oncologist at Cleveland Clinic Cancer Institute.